BMS provides update on Part 2 of CheckMate -227 trial to treat first-line non-squamous non-small cell lung cancer regardless of PD-L1 status

-Bristol-Myers Squibb Company announced that Part 2 of the Phase III CheckMate -227 trial did not meet the primary endpoint of overall survival (OS) with Opdivo (nivolumab) plus chemotherapy versus chemotherapy in patients with first-line non-squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 status (HR 0.86; 95% CI 0.69-1.08).

The median OS for patients treated with Opdivo plus chemotherapy was 18.83 months vs. 15.57 months for chemotherapy, and the landmark one-year OS was 67.3 percent vs. 59.2 percent, respectively. In an exploratory analysis of patients with first-line squamous NSCLC, the median OS was 18.27 months for Opdivo plus chemotherapy vs. 11.96 months for chemotherapy (HR 0.69; 95% CI 0.50-0.97). No new safety signals were observed. The company will share complete findings from this trial at an upcoming medical meeting.